Nicholas P Giustini, Colin C Pritchard, Nikhil V Kamat, Manoj P Menon
{"title":"<i>EGFR</i> V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.","authors":"Nicholas P Giustini, Colin C Pritchard, Nikhil V Kamat, Manoj P Menon","doi":"10.1200/PO.23.00215","DOIUrl":null,"url":null,"abstract":"<p><p>Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"8 ","pages":"e2300215"},"PeriodicalIF":5.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO precision oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/PO.23.00215","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
